Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
OBJECTIVE: To examine initiation of newer antiretroviral treatments across sociodemographic subgroups during the 3 years following the introduction of these treatments, and explore persistence on treatment and its association with patient characteristics.
DESIGN: Merged Medicaid paid claims and HIV/AIDS surveillance data were used to analyze use of protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) over time. Survival analysis techniques were used to analyze initiation of PI/NNRTI use. Ordinary least squares and logistic regression were used to determine predictors of persistence on PI/NNRTI therapy.
SETTING AND PARTICIPANTS: The study population consisted of 2,459 New Jersey non-HMO adult Medicaid beneficiaries with AIDS, identified through a match between HIV/AIDS Registry and Medicaid files. Their PI/NNRTI use was followed from March 1996, when the first PI was licensed, to the end of 1998.
MEASUREMENTS AND MAIN RESULTS: African Americans initiated treatment on average 8 months later than non-Hispanic whites; initiation of treatment was also slower for injection drug users and for those who did not receive case management through a Medicaid waiver program. These bivariate findings were confirmed with a multivariate time-to-treatment analysis using proportional hazards regression. Among those initiating PI/NNRTI use, 35% had discontinued it by the end of follow-up. Bivariate analyses of treated individuals found that PI/NNRTI use as a proportion of follow-up time was lower for African Americans and Hispanics, and higher for older individuals and for those receiving case management through a Medicaid waiver program, while injection drug use history was not associated with persistence. These findings were confirmed by a regression analysis, which found that controlling for other characteristics, African-American race, and Hispanic ethnicity were each associated with a significant 8% reduction in the proportion of time on PI/NNRTIs following initiation of treatment. Alternative approaches for modeling persistence produced similar results.
CONCLUSIONS: Results suggest that consistent longitudinal use is difficult for many patients. Persistence of use was lower for minority beneficiaries despite comparable coverage for pharmacy and other health services through Medicaid. Our findings suggest the need to examine nonfinancial barriers to appropriate use of highly active antiretroviral therapy, and to develop and test programmatic strategies for supporting patients in remaining on these regimens consistently.
- Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450–4. CrossRef
- Palella J, Frank J, Delaney KM, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–60. CrossRef
- Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society, USA panel. JAMA. 1997;277:1962–9. CrossRef
- Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA. 1997;277:145–53. CrossRef
- Fauci AS. AIDS in 1996: much accomplished, much to do. JAMA. 1996;276:155–6. CrossRef
- Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Morb Mortal Wkly Rep. 1998;47:43–82.
- Bonfanti P, Capetti A, Rizzardini G. HIV disease treatment in the era of HAART. Biomed Pharmacother. 1999;53:93–105. CrossRef
- Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81–7.
- Erice A, Mayers DL, Strike DG, et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med. 1993;328:1163–5. CrossRef
- Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307–11. CrossRef
- Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999;282:1135–41. CrossRef
- Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281:2305–15. CrossRef
- Bing EG, Kilbourne AM, Brooks RA, Lazarus EF, Senak M. Protease inhibitor use among a community sample of people with HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:474–80.
- Sorvillo F, Kerndt P, Odem S, et al. Use of protease inhibitors among persons with AIDS in Los Angeles County. AIDS Care. 1999;11:147–55. CrossRef
- Sackoff JE, McFarland JW, Shin SS. Trends in prescriptions for highly active antiretroviral therapy in four New York City HIV clinics. J AIDS. 2000;23:178–83.
- Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS. 1997;11:1665–70. CrossRef
- Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA. 1997;278:63–5. CrossRef
- Bayer R, Stryker J. Ethical challenges posed by clinical progress in AIDS. Am J Public Health. 1997;87:1599–602.
- Van Roon EN, Verzijl JM, Juttmann JR, Lenderink AW, Blans MJ, Egberts AC. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:290–4.
- Malow RM, McPherson S, Kilmas N, et al. Adherence to complex combination antiretroviral therapies by HIV-positive drug abusers. Alcohol Drug Abuse. 1998;49:1021–4.
- Kalichman SC, Ramachandran B, Catz S. Adherence to combination antiretroviral therapies in HIV patients of low health literacy. J Gen Intern Med. 1999;14:267–73. CrossRef
- Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13:1763–9. CrossRef
- Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19:124–33 Mar. CrossRef
- Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? J AIDS. 1999;21:114–9.
- Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J AIDS. 1998;18:117–225.
- Kastrissios H, Suarez JR, Hammer S, Katzenstein D, Blaschke TF. The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker. AIDS. 1998;12:2305–11. CrossRef
- Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS. 1999;13:1099–107. CrossRef
- Rigsby MO, Rosen MI, Beauvais JE, et al. Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med. 2000;15:841–7. CrossRef
- Laine C, Newschaffer CJ, Zhang D, Cosler L, Hauck WW, Turner BJ. Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis. Obstet Gynecol. 2000;95:167–73. CrossRef
- Crystal S, Sambamoorthi U, Merzel C. The diffusion of innovation in AIDS treatment: zidovudine use in two New Jersey cohorts. Health Serv Res. 1995;30:593–614.
- Broers B, Morabia A, Hirschel B. A cohort study of drug users’ compliance with zidovudine treatment. Arch Intern Med. 1994;154:1121–7. CrossRef
- Center for Medicaid and State Operations. Medicaid and acquired immune deficiency syndrome (AIDS) and human immunodeficiency virus (HIV) infection. http://www.hcfa.gov/medicaid/obs11.htm. April 2000.
- Berk ML, Schur CL. Access to care: how much difference does Medicaid make? Health Aff (Millwood). 1998;17:169–80. CrossRef
- Henry K. The case for more cautious, patient-focused antiretroviral therapy. Ann Intern Med. 2000;132:306–11.
- Regenstein M, Anthony SE. Medicaid managed care for persons with disabilities. Economic and Social Research Institute. August 1998. http://newfederalism.urban.org/html/occa11.html#medi.
- Turner BJ, Newschaffer CJ, Zhang D, et al. Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care. 2000;38:911–25. CrossRef
- Fasciano NJ, Cherlow AL, Turner BJ, Thornton CV. Profile of Medicare beneficiaries with AIDS: application of an AIDS case-finding algorithm. Health Care Financ Rev. 1998;19:19–38.
- Sambamoorthi U, Collins S, Crystal S. Characteristics of dually-eligible Medicaid beneficiaries. J Health Soc Policy. In press.
- Merzel C, Crystal S, Sambamoorthi U, Karus D, Kurland C. New Jersey’s Medicaid waiver for acquired immunodeficiency syndrome. Health Care Financ Rev. 1992;13:27–44.
- Diggle P, Liang KY, Zeger S. Analysis of Longitudinal Data. Oxford and New York: Oxford University Press; 1994.
- Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley and Sons, Inc.; 1980.
- Aday LA, Anderson RM. The national profile of access to medical care: where do we stand? Am J Public Health. 1984;74:1331–9.
- Bindman AB, Grumbach K, Osmond D, et al. Preventable hospitalizations and access in health care. JAMA. 1995;274:305–11. CrossRef
- Peterson ED, Wright SM, Daley J, Thibault GE. Racial variation in cardiac procedure use and survival following acute myocardial infarction in the department of veterans affairs. JAMA. 1994;271:1175–80. CrossRef
- Whittle J, Conigliaro J, Good CB, Joswiak M. Racial differences in the use of invasive cardiovascular procedures in the Department of Veterans Affairs medical system. N Engl J Med. 1993;329:621–7. CrossRef
- Carlisle DM, Leake BD, Shapiro MF. Racial and ethnic disparities in the use of cardiovascular procedures: associations with types of health insurance. Am J Public Health. 1997;87:263–7. CrossRef
- Gornick ME, Eggers PW, Reilly TW, et al. Effects of race and income on mortality and use of services among Medicare beneficiaries. N Engl J Med. 1996;335:791–9. CrossRef
- Satariano ER, Swanson GM, Moll PP. Nonclinical factors associated with surgery received for treatment of early stage breast cancer. Am J Public Health. 1992;82:195–8.
- Diehr P, Yergan J, Chu J, et al. The influence of race on the use of surgical procedures for treatment of peripheral vascular disease of the lower extremities. Arch Surg. 1995;130:381–6.
- Center for Disease Control. Fighting HIV/AIDS in African American communities: a growing crisis. http://www.cdc.gov/hiv/pubs/brochure/African-American.pdf; October 4, 2000.
- Fairfield KM, Libman H, Davis RB, Eisenberg DM, Phillips RS. Delays in protease inhibitor use in clinical practice. J Gen Intern Med. 1999;14:395–401. CrossRef
- Kitahata MM, Koepseli TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians’ experience with the acquired immunodeficiency syndrome as a factor in patients’ survival. N Engl J Med. 1996;334:701–6. CrossRef
- Wenger N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral adherence. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 1999. Abstract 98.
- Centers for Disease Control. AIDS among people aged 50 or older years—U.S., 1991–1996. JAMA. 1998;279:576. CrossRef
- Anderson K, Mitchell JM. Expenditures on services for persons with acquired immunodeficiency syndrome under a medicaid home- and community-based waiver program: are selection effects important? Med Care. 1997;35:425–39. CrossRef
- Department of Health and Senior Services. Division of AIDS Prevention and Control begins broad initiative to decrease perinatal transmission. AIDSline. 1999;11:1–2.
- Hakki M, Cinti SK. Gaps in pharmacy logs predict poor virologic outcome in HIV-infected patients on highly active antiretroviral therapy. Presented at the annual meeting of the Michigan Infectious Disease Society, Lansing, Mich, March 2000.
- Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis. 1999;29:824–30.
- Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS
Journal of General Internal Medicine
Volume 16, Issue 12 , pp 850-859
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- protease inhibitors
- Industry Sectors